EGFR and non-small cell lung carcinoma: For instance, 4-anilinoquinazoline inhibitors, such as gefitinib and erlotinib, have been designed to inhibit the tyrosine kinase domain of epidermal growth factor receptor (EGFR), which is overexpressed in NSCLC; such inhibitors are currently being used for the treatment of NSCLC [5–8].